

1 Novel genes for autism implicate both excitatory and inhibitory cell 2 lineages in risk 3

4 F. Kyle Satterstrom^{1,2,3,*}, Jack A. Kosmicki^{1,2,3,4,5,*}, Jiebiao Wang^{6,*}, Michael S. Breen^{7,8,9}, Silvia
5 De Rubeis^{7,8,9,†}, Joon-Yong An¹⁰, Minshi Peng⁶, Ryan Collins^{5,11}, Jakob Grove^{12,13,14}, Lambertus
6 Klei¹⁵, Christine Stevens^{1,3,4,5}, Jennifer Reichert^{7,8}, Maureen S. Mulhern^{7,8}, Mykyta Artomov^{1,3,4,5},
7 Sherif Gerges^{1,3,4,5}, Brooke Sheppard¹⁰, Xinyi Xu^{7,8}, Aparna Bhaduri^{16,17}, Utku Norman¹⁸,
8 Harrison Brand⁵, Grace Schwartz¹⁰, Rachel Nguyen¹⁹, Elizabeth E. Guerrero²⁰, Caroline
9 Dias^{21,22}, Branko Aleksic²³, Richard Anney²⁴, Mafalda Barbosa⁹, Somer Bishop¹⁰, Alfredo
10 Brusco^{25,26}, Jonas Bybjerg-Grauholm^{12,27}, Angel Carracedo^{28,29}, Marcus C.Y. Chan³⁰, Andreas
11 G. Chiochetti³¹, Brian H. Y. Chung³⁰, Hilary Coon^{32,33}, Michael L. Cuccaro³⁴, Aurora Currò³⁵,
12 Bernardo Dalla Bernardina³⁶, Ryan Doan²¹, Enrico Domenici³⁷, Shan Dong¹⁰, Chiara Fallerini³⁵,
13 Montserrat Fernández-Prieto^{28,38}, Giovanni Battista Ferrero³⁹, Christine M. Freitag³¹, Menachem
14 Fromer³, J. Jay Gargus¹⁹, Daniel Geschwind^{40,41}, Elisa Giorgio²⁵, Javier González-Peñas⁴²,
15 Stephen Guter⁴³, Danielle Halpern^{7,8}, Emily Hansen-Kiss⁴⁴, Xin He⁴⁵, Gail E. Herman⁴⁴, Irva
16 Hertz-Picciotto²⁰, David M. Hougaard^{12,27}, Christina M. Hultman⁴⁶, Iuliana Ionita-Laza⁴⁷, Suma
17 Jacob⁴³, Jesslyn Jamison^{7,8}, Astanand Jugessur⁴⁸, Miia Kaartinen⁴⁹, Gun Peggy Knudsen⁴⁸,
18 Alexander Kolevzon^{7,8,50}, Itaru Kushima²³, So Lun Lee³⁰, Terho Lehtimäki⁵¹, Elaine T. Lim⁴,
19 Carla Lintas⁵², W. Ian Lipkin⁴⁷, Diego Lopergolo³⁵, Fátima Lopes⁵³, Yunin Ludena²⁰, Patricia
20 Maciel⁵³, Per Magnus⁴⁸, Behrang Mahjani^{7,8}, Nell Maltman⁴³, Dara S. Manoach⁵⁴, Gal Meiri⁵⁵,
21 Idan Menashe⁵⁶, Judith Miller^{32,33}, Nancy Minshew¹⁵, Eduarda Montenegro M. de Souza⁵⁷,
22 Danielle Moreira⁵⁷, Eric M. Morrow⁵⁸, Ole Mors^{12,59}, Preben Bo Mortensen^{12,13,60,61}, Matthew
23 Mosconi⁴³, Pierandrea Muglia⁶², Benjamin Neale^{1,2,3}, Merete Nordentoft^{12,63}, Norio Ozaki²³,
24 Aarno Palotie^{2,3,64,65}, Mara Parellada⁴², Maria Rita Passos-Bueno⁵⁷, Margaret Pericak-Vance³⁴,
25 Antonio Persico^{66,67}, Isaac Pessah²⁰, Kaija Puura⁴⁹, Abraham Reichenberg^{7,8,9,68}, Alessandra
26 Renieri^{35,69}, Evelise Riberi³⁹, Elise B. Robinson^{1,2,3}, Kaitlin E. Samocha⁷⁰, Sven Sandin^{7,8,46},
27 Susan L. Santangelo^{71,72}, Gerry Schellenberg⁷³, Stephen W. Scherer^{74,75}, Sabine Schlitt³¹,
28 Rebecca Schmidt²⁰, Lauren Schmitt⁴³, Isabela Maya W. Silva⁵⁷, Tarjinder Singh^{1,2,3,4,5}, Paige M.
29 Siper^{7,8,9}, Moyra Smith¹⁹, Gabriela Soares⁷⁶, Camilla Stoltenberg⁴⁸, Pål Suren⁴⁸, Ezra
30 Susser^{77,78}, John Sweeney⁴³, Peter Szatmari⁷⁹, Lara Tang^{7,8}, Flora Tassone^{20,80}, Karoline
31 Teufel³¹, Elisabetta Trabetti⁸¹, Maria del Pilar Trelles^{7,8}, Christopher Walsh²¹, Lauren A. Weiss¹⁰,
32 Thomas Werge^{12,82,83}, Donna Werling¹⁰, Emilie M. Wigdor^{1,2,3}, Emma Wilkinson^{7,8}, Jeremy A.
33 Willsey¹⁰, Tim Yu²¹, Mullin H.C. Yu³⁰, Ryan Yuen⁷⁴, Elaine Zach⁵⁷, iPSYCH consortium,
34 Catalina Betancur^{84,†}, Edwin H. Cook^{43,†}, Louise Gallagher^{85,†}, Michael Gill^{85,†}, Thomas Lehner⁸⁶,
35 Geetha Senthil⁸⁶, James S. Sutcliffe^{87,88,†}, Audrey Thurm⁸⁶, Michael E. Zwick^{89,†}, Anders D.
36 Børglum^{12,13,14,90}, Matthew W. State¹⁰, A. Ercument Cicek^{6,18}, Michael E. Talkowski⁵, David J.
37 Cutler⁸⁹, Bernie Devlin^{15,†,#}, Stephan J. Sanders^{10,#,§}, Kathryn Roeder^{6,91,†,#,§}, Joseph D.
38 Buxbaum^{7,8,9,92,93,94,†,#,§}, Mark J. Daly^{1,2,3,4,5,64,†,#,§}

39
40
41 ¹Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts,
42 USA. ²Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts
43 General Hospital, Boston, Massachusetts, USA. ³Program in Medical and Population Genetics,
44 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. ⁴Harvard Medical School,
45 Boston, Massachusetts, USA. ⁵Center for Genomic Medicine, Department of Medicine,
46 Massachusetts General Hospital, Boston, Massachusetts, USA. ⁶Department of Statistics,

1 Carnegie Mellon University, Pittsburgh, Pennsylvania, USA.⁷Seaver Autism Center for
2 Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York,
3 USA.⁸Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New
4 York, USA.⁹The Mindich Child Health and Development Institute, Icahn School of Medicine at
5 Mount Sinai, New York, New York, USA.¹⁰Department of Psychiatry, UCSF Weill Institute for
6 Neurosciences, University of California San Francisco, San Francisco, California,
7 USA.¹¹Program in Bioinformatics and Integrative Genomics, Harvard Medical School, Boston,
8 Massachusetts, USA.¹²The Lundbeck Foundation Initiative for Integrative Psychiatric Research,
9 iPSYCH, Denmark.¹³Center for Genomics and Personalized Medicine, Aarhus,
10 Denmark.¹⁴Department of Biomedicine - Human Genetics, Aarhus University, Aarhus,
11 Denmark.¹⁵Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh,
12 Pennsylvania, USA.¹⁶Department of Neurology, University of California San Francisco, San
13 Francisco, California, USA.¹⁷The Eli and Edythe Broad Center of Regeneration Medicine and
14 Stem Cell Research, University of California San Francisco, San Francisco, California,
15 USA.¹⁸Computer Engineering Department, Bilkent University, Ankara, Turkey.¹⁹Center for
16 Autism Research and Translation, University of California Irvine, Irvine, California, USA.²⁰MIND
17 (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California
18 Davis, Davis, California, USA.²¹Division of Genetics, Boston Children's Hospital, Boston,
19 Massachusetts, USA.²²Division of Developmental Medicine, Boston Children's Hospital,
20 Boston, Massachusetts, USA.²³Department of Psychiatry, Graduate School of Medicine,
21 Nagoya University, Nagoya, Japan.²⁴Division of Psychological Medicine & Clinical
22 Neurosciences, MRC Centre for Neuropsychiatric Genetics & Genomics, Cardiff University,
23 Cardiff, United Kingdom.²⁵Department of Medical Sciences, University of Torino, Turin,
24 Italy.²⁶Medical Genetics Unit, Città della Salute e della Scienza Hospital, Turin, Italy.²⁷Center
25 for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut,
26 Copenhagen, Denmark.²⁸Grupo de Medicina Xenómica, Centro de Investigación en Red de
27 Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela, Santiago de
28 Compostela, Spain.²⁹Fundación Pública Galega de Medicina Xenómica, Servicio Galego de
29 Saúde (SERGAS), Santiago de Compostela, Spain.³⁰Department of Pediatrics & Adolescent
30 Medicine, Duchess of Kent Children's Hospital, The University of Hong Kong, Hong Kong
31 Special Administrative Region, China.³¹Department of Child and Adolescent Psychiatry,
32 Psychosomatics and Psychotherapy, Goethe University Frankfurt, Frankfurt,
33 Germany.³²Department of Internal Medicine, University of Utah, Salt Lake City, Utah,
34 USA.³³Department of Psychiatry, University of Utah, Salt Lake City, Utah, USA.³⁴John P
35 Hussman Institute for Human Genomics, University of Miami, Miami, USA.³⁵Medical Genetics,
36 University of Siena, Siena, Italy.³⁶Child Neuropsychiatry Department, Department of Surgical
37 Sciences, Dentistry, Gynecology and Pediatrics. University of Verona, Verona, Italy.³⁷Centre for
38 Integrative Biology, University of Trento, Trento, Italy.³⁸Neurogenetics Group, Instituto de
39 Investigación Sanitaria de Santiago (IDIS-SERGAS), Santiago de Compostela,
40 Spain.³⁹Department of Public Health and Pediatrics, University of Torino, Turin,
41 Italy.⁴⁰Department of Human Genetics, David Geffen School of Medicine, University of
42 California Los Angeles, Los Angeles, California, USA.⁴¹Center for Autism Research and
43 Treatment and Program in Neurobehavioral Genetics, Semel Institute, David Geffen School of
44 Medicine, University of California Los Angeles, Los Angeles, California, USA.⁴²Department of
45 Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IISGM,
46 CIBERSAM, School of Medicine Complutense University, Madrid, Spain.⁴³Institute for Juvenile
47 Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois,
48 USA.⁴⁴The Research Institute at Nationwide Children's Hospital, Columbus, Ohio,
49 USA.⁴⁵Department of Human Genetics, University of Chicago, Chicago, Illinois,
50 USA.⁴⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,
51 Sweden.⁴⁷Department of Biostatistics, Columbia University, New York, New York,

1 USA. ⁴⁸Norwegian Institute of Public Health, Oslo, Norway. ⁴⁹Department of Child Psychiatry,
2 University of Tampere and Tampere University Hospital, Tampere, Finland. ⁵⁰Department of
3 Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA. ⁵¹Department
4 of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-
5 Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere,
6 Finland. ⁵²Campus Bio-medico, Rome, Italy. ⁵³Life and Health Sciences Research Institute,
7 School of Medicine, University of Minho, Campus de Gualtar, Braga, Portugal. ⁵⁴Department of
8 Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston,
9 Massachusetts, USA. ⁵⁵Pre-School Psychiatry Unit, Soroka University Medical Center, Beer
10 Sheva, Israel. ⁵⁶Department of Public Health, Ben-Gurion University of the Negev, Beer-Sheva,
11 Israel. ⁵⁷Centro de Pesquisas sobre o Genoma Humano e Células tronco, Departamento de
12 Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo,
13 Brazil. ⁵⁸Department of Molecular Biology, Cell Biology and Biochemistry and Department of
14 Psychiatry and Human Behavior, Brown University, Providence, Rhode Island,
15 USA. ⁵⁹Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark. ⁶⁰National
16 Centre for Register-Based Research, Aarhus University, Aarhus, Denmark. ⁶¹Centre for
17 Integrated Register-based Research, Aarhus University, Aarhus, Denmark. ⁶²UCB Pharma,
18 Belgium. ⁶³Mental Health Services in the Capital Region of Denmark, Mental Health Center
19 Copenhagen, University of Copenhagen, Copenhagen, Denmark. ⁶⁴Institute for Molecular
20 Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. ⁶⁵Psychiatric &
21 Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital,
22 Boston, Massachusetts, USA. ⁶⁶Interdepartmental Program “Autism 0-90”, Gaetano Martino
23 University Hospital, University of Messina, Messina, Italy. ⁶⁷Mafalda Luce Center for Pervasive
24 Developmental Disorders, Milan, Italy. ⁶⁸Department of Environmental Medicine and Public
25 Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA. ⁶⁹Genetica
26 Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy. ⁷⁰The Wellcome Trust Sanger
27 Institute, Cambridge, United Kingdom. ⁷¹Maine Medical Center and Maine Medical Center
28 Research Institute, Portland, Maine, USA. ⁷²Department of Psychiatry, Tufts University School
29 of Medicine, Boston, Massachusetts, USA. ⁷³Department of Pathology and Laboratory Medicine,
30 University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. ⁷⁴Program in
31 Genetics and Genome Biology, The Centre for Applied Genomics, The Hospital for Sick
32 Children, Toronto, Ontario, Canada. ⁷⁵McLaughlin Centre, University of Toronto, Toronto,
33 Ontario, Canada. ⁷⁶Center for Medical Genetics Dr. Jacinto Magalhães, National Health Institute
34 Dr. Ricardo Jorge, Porto, Portugal. ⁷⁷New York State Psychiatric Institute, New York, New York,
35 USA. ⁷⁸Department of Epidemiology, Mailman School of Public Health, Columbia University,
36 Epidemiology, Mailman School of Public Health, Columbia University, New York, New York,
37 USA. ⁷⁹Department of Psychiatry and Behavioural Neurosciences, Offord Centre for Child
38 Studies, McMaster University, Hamilton, Ontario, Canada. ⁸⁰Department of Biochemistry and
39 Molecular Medicine, University of California Davis, School of Medicine, Davis, CA,
40 USA. ⁸¹Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology
41 and Genetics, University of Verona, Verona, Italy. ⁸²Institute of Biological Psychiatry, MHC Sct.
42 Hans, Mental Health Services Copenhagen, Roskilde, Denmark. ⁸³Department of Clinical
43 Medicine, University of Copenhagen, Copenhagen, Denmark. ⁸⁴Sorbonne Université, INSERM,
44 CNRS, Neuroscience Paris Seine, Institut de Biologie Paris Seine, Paris, France. ⁸⁵Department
45 of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland. ⁸⁶National Institute of
46 Mental Health, National Institutes of Health, Bethesda, Maryland, USA. ⁸⁷Vanderbilt Genetics
47 Institute, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. ⁸⁸Department of
48 Molecular Physiology and Biophysics and Psychiatry, Vanderbilt University School of Medicine,
49 Nashville, Tennessee, USA. ⁸⁹Department of Human Genetics, Emory University School of
50 Medicine, Atlanta, Georgia, USA. ⁹⁰Bioinformatics Research Centre, Aarhus University, Aarhus,
51 Denmark. ⁹¹Computational Biology Department, Carnegie Mellon University, Pittsburgh,

1 Pennsylvania, USA. ⁹²Department of Genetics and Genomic Sciences, Icahn School of
2 Medicine at Mount Sinai, New York, New York, USA. ⁹³Friedman Brain Institute, Icahn School of
3 Medicine at Mount Sinai, New York, New York, USA. ⁹⁴Department of Neuroscience, Icahn
4 School of Medicine at Mount Sinai, New York, New York, USA.

5

6

7

8

9 * Equal contribution

10 § Equal contribution

11 † Lead member of standing committee of the ASC

12 # ASC Principal Investigators

13

1 **Abstract**

2

3 We present the largest exome sequencing study to date focused on rare variation in autism
4 spectrum disorder (ASD) (n=35,584). Integrating *de novo* and case-control variation with an
5 enhanced Bayesian framework incorporating evolutionary constraint against mutation, we
6 implicate 99 genes in ASD risk at a false discovery rate (FDR) ≤ 0.1 . Of these 99 risk genes, 46
7 show higher frequencies of disruptive *de novo* variants in individuals ascertained for severe
8 neurodevelopmental delay, while 50 show higher frequencies in individuals ascertained for ASD,
9 and comparing ASD cases with disruptive mutations in the two groups shows differences in
10 phenotypic presentation. Expressed early in brain development, most of the risk genes have roles
11 in neuronal communication or regulation of gene expression, and 12 fall within recurrent copy
12 number variant loci. In human cortex single-cell gene expression data, expression of the 99 risk
13 genes is also enriched in both excitatory and inhibitory neuronal lineages, implying that
14 disruption of these genes alters the development of both neuron types. Together, these insights
15 broaden our understanding of the neurobiology of ASD.

16

1 Introduction

2
3 Autism spectrum disorder (ASD), a childhood-onset neurodevelopmental condition characterized
4 by deficits in social communication and restricted, repetitive patterns of behavior or interests (1),
5 affects more than 1% of children (2). Multiple studies have demonstrated high heritability,
6 indicating that genetic factors play an important, causal role (3). Although common genetic
7 variants, which are present to a greater or lesser degree in everyone, account for the majority of
8 the observed heritability (4), rare inherited variants and newly arising, or *de novo*, mutations are
9 major contributors to individual risk (5-14). When this rare variation disrupts a gene in
10 individuals with ASD more often than expected by chance, it implicates that gene in risk (5, 10,
11 11, 15, 16). Such genes, in turn, can provide insight into the atypical neurodevelopment
12 underlying ASD, both individually (17, 18) and *en masse* (5, 10, 19). Fundamental questions
13 about the nature of this disrupted neurobiological development – including when it occurs,
14 where, and in what cell types – remain unanswered. Here we present the largest exome
15 sequencing study in ASD to date, greatly expanding the list of genes significantly associated
16 with ASD, and combine these results with functional genomic data to gain novel insights into the
17 neurobiology of ASD.

18
19 Building on previous Autism Sequencing Consortium (ASC) studies (5, 10, 20), we analyze
20 35,584 samples, including 11,986 ASD cases split almost evenly between family-based cohorts
21 (6,430 cases [“probands”] with both parents sequenced, enabling *de novo* mutations to be
22 detected) and case-control cohorts (5,556 cases with 8,809 ancestry-matched controls). We
23 introduce an enhanced Bayesian analytic framework, which leverages recently developed gene-
24 and variant-level scores of evolutionary constraint of genetic variation, to implicate genes in

1 ASD more rigorously than previous studies. In this way, we identify 99 genes likely to play a
2 role in ASD risk (false discovery rate [FDR] ≤ 0.1) and confirm that they are strongly enriched
3 for genes involved in gene expression regulation (GER) or neuronal communication (NC).
4 Furthermore, by analysis of extant gene expression data, we show that many of the GER genes
5 are expressed in multiple tissues throughout the body and reach a peak of cortical expression in
6 early fetal development, whereas many NC genes are expressed predominantly in the brain and
7 reach a peak of cortical expression in late fetal and perinatal development. Considering data from
8 single cells in the developing human cortex, most of the 99 ASD genes are highly expressed
9 from midfetal development onwards, and both the GER and NC sets are enriched in maturing
10 and mature excitatory and inhibitory neurons.

11
12 The symptoms of ASD often occur in tandem with comorbidities. In at least a third of
13 individuals, ASD is one of a constellation of symptoms of neurodevelopmental delay (NDD),
14 alongside intellectual disability (2) and motor impairments (21). Unsurprisingly, many ASD
15 genes are also associated with NDD (22-26). By comparing disruptive *de novo* variants in our
16 study to those from NDD cohorts, we split the 99 genes into those with a higher frequency in
17 ASD-ascertained subjects (“ASD-predominant” or “ASD_P”) and those with a higher frequency in
18 NDD-ascertained subjects (“ASD_{NDD}”). We show that disruptive variants in ASD_{NDD} genes
19 result in higher rates of neurodevelopmental comorbidities even in ASD-ascertained subjects,
20 suggesting extreme selective pressure, while disruptive variants in ASD_P genes yield phenotypes
21 closer to ASD cases without ASD-associated variants, suggesting more modest selective
22 pressures. These distinctions suggest complex genotype-phenotype correlations across
23 neurodevelopmental domains, similar to those observed across tissues in well-defined genetic
24 syndromes.

1

2 **Results**

3

4 **Data generation and quality control**

5 Our primary goal is to associate genes with risk for ASD by examining the distribution of genetic
6 variation found in them. To do this, we integrated whole-exome sequence (WES) data from
7 several sources. After reported family structures were verified and stringent filters were applied
8 for sample, genotype, and variant quality, we included 35,584 samples (11,986 ASD cases) in
9 our analyses. These WES data included 21,219 family-based samples (6,430 ASD cases, 2,179
10 sibling controls, and both of their parents) and 14,365 case-control samples (5,556 ASD cases,
11 8,809 controls) (Fig. S1; Table S1). Read-level WES data were processed for 24,022 samples
12 (67.5%), including 6,197 newly sequenced ASC samples, using BWA (27) to perform alignment
13 and GATK (28) to perform joint variant calling (Fig. S1). These data were integrated with
14 variant- or gene-level counts from an additional 11,562 samples (Fig. S1), including 10,025
15 samples from the Danish iPSYCH study which our consortium had not previously incorporated
16 (29).

17

18 From this cohort, we identified a set of 10,552 rare *de novo* variants in protein-coding exons
19 (allele frequency $\leq 0.1\%$ in our dataset as well as the non-psychiatric subsets of the reference
20 databases ExAC and gnomAD (30)), with 70% of probands and 67% of unaffected offspring
21 carrying at least one *de novo* variant (4,521 out of 6,430 and 1,468 out of 2,179, respectively;
22 Table S2; Fig. S1). For rare inherited and case-control variant analyses, we included variants
23 with an allele count no greater than five in our dataset and in the non-psychiatric subset of ExAC

1 (30, 31). Analyses of inherited variation use only the family-based data, specifically comparing
2 variants that were transmitted or untransmitted from parents to their affected offspring.

3

4 **Impact of genetic variants on ASD risk**


5 Exonic variants can be divided into groups based on their predicted functional impact. For any
6 such group, the differential burden of variants carried by cases versus controls reflects the
7 average liability that these variants impart for ASD. This ASD liability, along with the mutation
8 rate per gene, can be used to determine the number of mutations required to demonstrate ASD
9 association for a specific gene (5, 10, 11). For example, because protein-truncating variants
10 (PTVs, consisting of nonsense, frameshift, and essential splice site variants) show a much greater
11 difference in burden between ASD cases and controls than missense variants, their average
12 impact on liability must be larger (15). Recent analyses have shown that additional measures of
13 functional severity, such as the “probability of loss-of-function intolerance” (pLI) score (30, 31)
14 and the integrated “missense badness, PolyPhen-2, constraint” (MPC) score (32), can further
15 delineate specific variant classes with a higher burden in ASD cases.

16

17 We divided the list of rare autosomal genetic variants into seven tiers of predicted functional
18 severity. Three tiers for PTVs by pLI score (≥ 0.995 , 0.5-0.995, 0-0.5), in order of decreasing
19 expected impact on liability; three tiers for missense variants by MPC score (≥ 2 , 1-2, 0-1), also
20 in order of decreasing impact; and a single tier for synonymous variants, which should have
21 minimal impact on liability. We also divided the variants into three bins by their inheritance
22 pattern: *de novo*, inherited, and case-control, with the latter reflecting a mixture of *de novo* and
23 inherited variants that cannot be distinguished directly without parental data. Unlike inherited
24 variants, newly arising *de novo* mutations are exposed to minimal selective pressure and,

1 accordingly, have the potential to mediate substantial risk to severe disorders that limit fecundity,
2 such as ASD (33). This expectation is borne out by the substantially higher proportions of all
3 three PTV tiers and the two most severe missense variant tiers in *de novo* variants compared to
4 inherited variants (Fig. 1A). *De novo* mutations are also extremely rare, with 1.23 variants per
5 subject distributed over the 17,484 genes assessed, so the overall proportions of variants in the
6 case-control data are similar to those of inherited variants (Fig. 1A).

7



1 **Figure 1. Distribution of rare autosomal protein-coding variants in ASD cases and controls.**
2 *A*, The proportion of rare autosomal genetic variants split by predicted functional consequences,
3 represented by color, is displayed for family-based data (split into *de novo* and inherited
4 variants) and case-control data. PTVs and missense variants are split into three tiers of
5 predicted functional severity, represented by shade, based on the pLI and MPC metrics,
6 respectively. **B**, The relative difference in variant frequency (i.e. burden) between ASD cases and
7 controls (top and bottom) or transmitted and untransmitted parental variants (middle) is shown
8 for the top two tiers of functional severity for PTVs (left and center) and the top tier of functional
9 severity for missense variants (right). Next to the bar plot, the same data are shown divided by
10 sex. **C**, The relative difference in variant frequency shown in ‘B’ is converted to a trait liability z-
11 score, split by the same subsets used in ‘A’. For context, a z-score of 2.18 would shift an
12 individual from the population mean to the top 1.69% of the population (equivalent to an ASD
13 threshold based on 1 in 68 children (34)). No significant difference in liability was observed
14 between males and females for any analysis. Statistical tests: B, C: Binomial Exact Test (BET)
15 for most contrasts; exceptions were “both” and “case-control”, for which Fisher’s method for
16 combining BET p-values for each sex and, for case-control, each population, was used; p-values
17 corrected for 168 tests are shown. Abbreviations: PTV: protein-truncating variant; pLI:
18 probability loss-of-function intolerant; MPC: missense badness, PolyPhen-2, and constraint;
19 RR: relative risk.

20
21 Comparing affected probands to unaffected siblings, we observe a 4.4-fold enrichment for *de*
22 *novo* PTVs in the 1,447 autosomal genes with a pLI ≥ 0.995 (366 in 6,430 cases versus 36 in
23 2,179 controls; 0.074 vs. 0.017 variants per sample (vps); $p=5 \times 10^{-19}$; Fig. 1B). A less
24 pronounced difference in burden is observed for rare inherited PTVs in these genes, with a 1.2-
25 fold enrichment for transmitted versus untransmitted alleles (695 transmitted versus 557
26 untransmitted in 5,869 parents; 0.12 vs. 0.10 vps; $p=0.07$; Fig. 1B). The relative burden in the
27 case-control data falls between the estimates for *de novo* and inherited data in these most severe
28 PTVs, with a 1.8-fold enrichment in cases versus controls (874 in 5,556 cases versus 759 in
29 8,809 controls; 0.16 vs. 0.09 vps; $p=4 \times 10^{-24}$; Fig. 1B). Analysis of the middle tier of PTVs ($0.5 \leq$
30 $pLI < 0.995$) shows a similar, but muted, pattern (Fig. 1B), while the lowest tier of PTVs ($pLI <$
31 0.5) shows no case enrichment (Table S3).

32
33 *De novo* missense variants are observed more frequently than *de novo* PTVs and, *en masse*, they
34 show only marginal enrichment over the rate expected by chance (5) (Fig. 1). However, the most

1 severe missense variants ($MPC \geq 2$) occur at a similar frequency to *de novo* PTVs, and we
2 observe a 2.2-fold case enrichment (354 in 6,430 cases versus 58 in 2,179 controls; 0.057 vs.
3 0.027 vps; $p=3 \times 10^{-5}$; Fig. 1B), with a consistent 1.2-fold enrichment in the case-control data
4 (4,277 in 5,556 cases versus 6,149 in 8,809 controls; 0.80 vs. 0.68 vps; $p=4 \times 10^{-7}$; Fig. 1B). Of
5 note, this top tier of missense variation shows stronger enrichment in cases than the middle tier
6 of PTVs. Consistent with prior expectations, the other two tiers of missense variation were not
7 enriched in cases (Table S3).

8

9 **Sex differences in ASD risk**

10 The prevalence of ASD is consistently higher in males than females, usually by a factor of three
11 or more (2). Females diagnosed with ASD carry a higher burden of genetic risk factors,
12 including *de novo* copy number variants (CNVs) (9, 10), *de novo* PTVs (5, 31), and *de novo*
13 missense variants (5). Here we observe a similar result, with a 2-fold enrichment of *de novo*
14 PTVs in highly constrained genes in affected females versus affected males ($p=3 \times 10^{-6}$) and
15 similar non-significant trends in other categories with large differences between cases and
16 controls (Fig. 1B; Table S3). The excess of genetic risk we observe in females is consistent with
17 a model dubbed the female protective effect (FPE) that postulates females being more resilient to
18 ASD and consequently requiring an increased genetic load (in this case, deleterious variants of
19 larger effect) to reach the threshold for a diagnosis (35, 36). The converse hypothesis is that risk
20 variation has larger effects in males than in females so that females require a higher genetic
21 burden to reach the same diagnostic threshold as males.


22

23 To discern between these two possibilities, we assessed the ASD trait liability in males and
24 females using sex-specific estimates of ASD prevalence (34). Relative to the general population,

1 ASD can be conceptualized as the extreme tail of a normally distributed quantitative trait, termed
2 “liability,” with individuals who cross a liability threshold receiving the diagnostic label of ASD.
3 The threshold is determined by ASD prevalence, estimated at 2.38% in males and 0.53% in
4 females (34). Using this model and the relative burden of variants in cases and controls (Table
5 S3), we can estimate the impact that different classes of genetic variants would have on liability
6 (Supplemental Online Methods (SOM)) and, in theory, all sources of risk can be calibrated to
7 this common metric. For context, the observed ASD prevalence maps onto a trait liability
8 threshold with a z-score of 1.98 in males and 2.56 in females. Across all classes of genetic
9 variants, we observed no significant sex differences in trait liability, consistent with the FPE
10 model (Fig. 1C).

11
12 **Differences in ASD liability**
13 In the absence of sex-specific differences in liability, we estimated the liability across both sexes
14 together. PTVs in any of the 1,447 genes with a pLI \geq 0.995 have a liability z-score of 0.59 when
15 *de novo*, compared to 0.24 in case-control populations and 0.09 for inherited variants (Fig. 1C;
16 Table S3). These liability z-scores, reflecting a higher ratio of true ASD risk variants to variants
17 with minimal or neutral impact on ASD risk in *de novo* variants compared to the other two
18 groups, can be leveraged to enhance gene discovery.

19



1
2 **Figure 2. Gene discovery in the ASC cohort.** *A*, An overview of gene discovery. Whole exome
3 sequencing data from 35,584 samples is entered into a Bayesian analysis framework (TADA)
4 that incorporates pLI score for PTVs and MPC score for missense variants. *B*, The model
5 identifies 99 autosomal genes associated with ASD at a false discovery rate (FDR) threshold of \leq
6 0.1, which is shown on the y-axis of this Manhattan plot with each point representing a gene. Of
7 these, 75 exceed the threshold of $FDR \leq 0.05$ and 25 exceed the threshold family-wise error rate
8 ($FWER \leq 0.05$). *C*, Repeating our ASD trait liability analysis (Fig. 1C) restricted to variants
9 observed within the 99 ASD-associated genes only. Statistical tests: *B*, TADA; *C*, Binomial Exact
10 Test (BET) for most contrasts; exceptions were “both” and “case-control”, for which Fisher’s
11 method for combining BET p-values for each sex and, for case-control, each population, was
12 used; p-values corrected for 168 tests are shown. Abbreviations: PTV: protein-truncating
13 variant; pLI: probability loss-of-function intolerant; MPC: missense badness, PolyPhen-2, and
14 constraint.

1 ASD gene discovery


2 An ASD-associated gene can be identified by an excess of variants in affected individuals
3 compared to the expected count, which can be based on the per-gene mutation rates and sample
4 size for *de novo* mutations or the relative frequency of classes of variants in controls. The
5 average risk carried by variants of a particular type (e.g., PTVs) is conveyed by the relative
6 liabilities (Fig. 1). For our earlier published work, we used the Transmitted And *De novo*
7 Association (TADA) model (15) to integrate missense and PTVs that are *de novo*, inherited, or
8 from case-control populations to stratify autosomal genes by FDR for association (5, 10). Here,
9 we update the TADA model to include pLI score as a continuous metric for PTVs and MPC
10 score in two tiers (≥ 2 , 1-2) for missense variants (Supplemental Methods and Fig. S2, S3). In
11 family data we include *de novo* PTVs as well as *de novo* missense variants in the model, while
12 for case-control we include only PTVs, which show the largest liability; we do not include
13 inherited variants due to the limited liabilities observed (Fig. 1C). These modifications result in
14 an enhanced TADA model that has greater sensitivity and accuracy than the original model
15 (Supplementary Methods).

16
17 Considering only *de novo* variants observed in WES data from our previous publication (10), the
18 original TADA model identifies 31 genes at $FDR \leq 0.1$. Keeping this FDR threshold constant,
19 applying the original TADA model to the *de novo* variants of the new ASC cohort of 35,584
20 samples identifies 65 ASD-associated genes. Integrating the pLI and MPC scores into the
21 enhanced TADA model boosts this to 85 genes. Finally, integrating the case-control data
22 identifies 99 ASD-associated genes at $FDR \leq 0.1$, of which 75 meet the more stringent threshold
23 of $FDR \leq 0.05$, while 25 are significant after Bonferroni correction (Fig. 2B; Table S4). Three
24 additional genes reach $FDR \leq 0.1$ (*KDM5B*, *RAI1*, and *EIF3G*) but are excluded from our high

1 confidence lists because they demonstrate an excess of *de novo* PTVs in unaffected siblings,
2 suggesting the possibility that the mutational model may underestimate their true mutation rate
3 (Supplementary Methods). Of note, however, heterozygous loss of *RAI1* expression is known to
4 cause the neurodevelopmental disorder Smith-Magenis syndrome (37).

5
6 By simulation experiments (described in the Supplementary Methods), we demonstrate the
7 reliable performance of the refined TADA model, in particular showing that our risk gene list,
8 with $FDR \leq 0.1$, is properly calibrated (Fig. S2). Of the 99 ASD-associated genes, 58 were not
9 discovered by our earlier analyses. The patterns of liability seen for these 99 genes are similar to
10 that seen over all genes (compare Fig. 2C versus Fig. 1C), although the effects of variants are
11 uniformly larger, as would be expected for this selected list of putative risk genes that would be
12 enriched for true risk variants. Note that, in keeping with the theory underlying the “winner’s
13 curse,” we would expect liability to be overestimated for some of these genes, specifically those
14 with the least evidence for association.

15



1
2 **Figure 3. Genetic characterization of ASD genes.** *A*, Count of PTVs versus missense variants
3 (MPC ≥ 1) in cases for each ASD-associated gene (red points, selected genes labeled). These
4 counts reflect the data used by TADA for association analysis: de novo and case/control data for
5 PTVs; de novo only for missense. *B*, Location of ASD de novo missense variants in the DEAF1
6 transcription factor. The five ASD mutations (marked in red) are in the SAND DNA-binding
7 domain (amino acids 193 to 273, spirals show alpha helices, arrows show beta sheets, KDWK is
8 the DNA binding-motif (38)) alongside ten variants observed in NDD, several of which have
9 been shown to reduce DNA binding, including Q264P and Q264R (39-41). *C*, The location of
10 four ASD missense variants are shown in the gene KCNQ3, which encodes the protein K_v7.3,
11 which forms a neuronal voltage-gated potassium channel in combination with KCNQ2/K_v7.2. All
12 four ASD variants were located in the voltage sensor (fourth of six transmembrane domains),
13 with three in the same residue (R230), including the gain-of-function R230C mutation (42)
14 observed in NDD (41). Five inherited variants observed in benign infantile seizures are shown in
15 the pore loop (43, 44). *D*, The location of four ASD missense variants in SCN1A, which encodes
16 the voltage-gated sodium channel Na_v1.1, alongside 17 de novo variants in NDD and epilepsy
17 (41). *E*, The location of eight ASD missense variants in SLC6A1, which encodes the neuronal
18 GABA-transporter GAT-1, alongside 31 de novo variants in NDD and epilepsy (41, 45). *F*,
19 Subtelomeric 2q37 deletions are associated with facial dysmorphisms, brachydactyly, high BMI,
20 neurodevelopmental delay, and ASD (46). While three genes within the locus have a pLI score \geq
21 0.995, only HDLBP, which encodes an RNA-binding protein, is associated with ASD. *G*,
22 Deletions at the 11q13.2-q13.4 locus have been observed in NDD, ASD, and otodental
23 dysplasia (47-49). Five genes within the locus have a pLI score ≥ 0.995 , including two ASD-

1 associated genes: *KMT5B* and *SHANK2*. **H**, Assessment of gene-based enrichment, via MAGMA,
2 of 99 ASD-associated genes against genome-wide significant common variants from six genome-
3 wide association studies (GWAS). **I**, Gene-based enrichment of 99 ASD-associated genes in
4 multiple GWAS as a function of effective cohort size. The GWAS used for each disorder in 'I' has
5 a black outline. Statistical tests: F, G, TADA; H, I, MAGMA. Abbreviations: ADHD: attention
6 deficit hyperactivity disorder, C: C-terminus; LMO4: LIM domain only 4; MYND: Myeloid
7 translocation protein 8, Nery, and DEAF1; N: N-terminus; NDD: neurodevelopmental delay;
8 NLS: Nuclear localization signal; SAND: Sp-100, AIRE, NucP41/ 75, and DEAF1.

9 10 **Patterns of mutations in ASD genes**

11 Within the set of observed mutations, the ratio of PTVs to missense mutations varies
12 substantially between genes (Fig. 3A). Some genes, such as *ADNP*, reach our association
13 threshold through PTVs alone, and three genes stand out as having an excess of PTVs, relative to
14 missense mutations, based on gene mutability: *SYNGAP1*, *DYRK1A*, and *ARID1B* (binomial test,
15 $p < 0.0005$). Because of the increased cohort size, availability of the MPC metric, and integration
16 of these into the enhanced TADA model, we are able for the first time to associate genes with
17 ASD based on *de novo* missense variation alone, as in the case of *DEAF1*. While we expect
18 PTVs to act primarily through haploinsufficiency, missense variants can both reduce or alter
19 gene function, often referred to as loss-of-function and gain-of-function, respectively. When
20 missense variants cluster in protein domains, they can provide insight into the direction of
21 functional effect and reveal genotype-phenotype correlations (5, 17). We therefore considered
22 the location of variants within four genes with four or more *de novo* missense variants and one or
23 no PTVs (Fig. 3A; Table S5).

24
25 We observe five *de novo* missense variants and no PTVs in *DEAF1*, which encodes a self-
26 dimerizing transcription factor involved in neuronal differentiation (38). Consistent with the idea
27 that ASD risk from *DEAF1* is primarily mediated by missense variation, multiple PTVs are
28 present in *DEAF1* in the ExAC control population (30), resulting in a pLI score of 0 and
29 indicating that heterozygous PTVs are likely benign. All five missense variants are in the SAND

1 domain (Fig. 3B), which is critical for both dimerization and DNA binding (38, 50). A similar
2 pattern of SAND domain missense enrichment and no PTVs is observed in individuals with
3 intellectual disability, speech delay, and behavioral abnormalities (39-41). Functional analyses of
4 several SAND domain missense variants reported reduced DNA binding (39, 51) rather than
5 gain-of-function effects, although given that haploinsufficiency via PTVs does not appear to
6 phenocopy this result, there may be an unforeseen gain of function or dominant negative impact.
7
8 Four *de novo* missense variants and no PTVs are observed in the gene *KCNQ3*, which encodes
9 the K_v7.3 subunits of a neuronal voltage-gated potassium channel. All four cases have comorbid
10 intellectual disability. The K_v7.2 subunits are encoded by the gene *KCNQ2*, with four K_v7.2 or
11 K_v7.3 subunits forming a channel (Fig. 3C). This family of potassium channels is responsible for
12 the M-current, which reduces neuronal excitability following action potentials. Loss-of-function
13 missense variants in both *KCNQ2* and *KCNQ3* are associated with benign familial neonatal
14 epilepsy (BFNE), while gain-of-function variants with persistent current have been associated
15 with NDD and/or epileptic encephalopathy (42). All four *de novo* missense variants in ASD
16 cases are within six residues of each other in the voltage-sensing fourth transmembrane domain,
17 with three at a single residue previously characterized as gain-of-function in NDD (R230C, Fig.
18 3C) (42). All the variants replace one of the critical positively charged arginine residues,
19 significantly reducing the domain's net positive charge and therefore its attraction to the
20 electronegative cell interior. This makes a compelling case for an etiological role in the gain-of-
21 function phenotype, and our data extend this gain-of-function phenotype to include ASD.
22 Furthermore, the observation of seizures in loss-of-function and risk for the ASD-NDD spectrum
23 in gain-of-function of these hyperpolarizing potassium channels is almost the opposite of that
24 observed in *SCN2A*, which encodes the depolarizing voltage-gated sodium channel Nav1.2. In

1 *SCN2A*, mild gain-of-function variants lead to BFNE, while PTVs and loss-of-function missense
2 variants, expected to be hyperpolarizing, lead to ASD and NDD (5, 11, 17). Considering the
3 other genes strongly associated with BFNE, we observe one *de novo* PTV in *KCNQ2*
4 (FDR=0.48) and no putative risk-mediating variants in *PRRT2*.

5
6 *SCN1A*, which encodes the voltage-gated sodium channel Nav1.1 and is a paralogue of *SCN2A*
7 (52), is strongly associated with Dravet syndrome, a form of progressive epileptic
8 encephalopathy including febrile, myoclonic, and/or generalized seizures, EEG abnormalities,
9 and NDD (53). Previous studies observed that up to 67% of children with Dravet syndrome also
10 meet diagnostic criteria for ASD (54-56). In keeping with these findings, we observe statistical
11 association between *SCN1A* and ASD in our cohort (FDR=0.05, TADA). Four cases have *de*
12 *nov*o missense variants with MPC ≥ 1 in *SCN1A* (Fig. 3A; Table S5), with three of these being
13 located in the C-terminus (57); all four cases are reported to have seizures, though details of
14 seizure onset, severity, or type are not available. In epileptic encephalopathy cohorts, PTVs are
15 the predominant mutation type; in contrast, missense variants are the more common type in ASD
16 and NDD (Fig. 3D). Electrophysiological analysis would be required to distinguish mild loss-of-
17 function from gain-of-function effects for these ASD-ascertained variants.

18
19 The gene *SLC6A1* encodes GAT-1, a voltage-gated GABA transporter. *SLC6A1* was previously
20 associated with developmental delay and cognitive impairment (23, 41), while a case series
21 highlighted its role in myoclonic atonic epilepsy (MAE) and absence seizures (45). Here, we
22 extend the phenotypic spectrum to include ASD, through the observation of eight *de novo*
23 missense variants (MPC ≥ 1) and one PTV in the case-control cohort (Fig. 3E). Four of these
24 missense variants are in the highly conserved sixth transmembrane domain, with one being

1 recurrent in two independent cases (A288V). Of the six ASD cases with seizure status available,
2 five have seizures reported; four of the ASD cases have data available on cognitive performance
3 and all four have intellectual disability. In cases ascertained for MAE, PTVs account for 54% (7
4 PTV, 6 missense) of observed *de novo* variants (45), and several of the missense variants reduce
5 GABA transport (58). By contrast, in our cases ascertained for ASD, only 11% are PTVs (1
6 PTV, 8 missense), while cases ascertained for developmental delay fall in between (30%; 3 PTV,
7 7 missense) (41). This trend may reflect underlying correlations between genotype, protein
8 function, and phenotype correlations, although further functional assessment is required to
9 confirm this.

10

11 **ASD genes within recurrent copy number variants (CNVs)**

12 Large CNVs encompassing certain genomic loci represent another important source of risk for
13 ASD (e.g. 16p11.2 microdeletions) (10). However, these genomic disorder (GD) segments can
14 include dozens of genes, which has impeded the identification of discrete dominant-acting
15 (“driver”) gene(s) within these regions. We sought to determine whether the 99 TADA-defined
16 genes could nominate dosage-sensitive genes within GD regions. We first curated a consensus
17 GD list from nine sources, totaling 823 protein-coding genes in 51 autosomal GD loci associated
18 with ASD or ASD-related phenotypes, including NDD (Table S6).

19

20 Within the 51 GDs were 12/99 (12.1%) ASD genes that localized to 11/51 (21.6%) GD loci
21 (after excluding *RAI1*, as described above; Table S6). Using multiple permutation strategies (see
22 Supplementary Methods), we found that this observed result was greater than expected by
23 chance when simultaneously controlling for number of genes, PTV mutation rate, and brain
24 expression levels per gene (2.2-fold increase; $p=5.8 \times 10^{-3}$). These 11 GD loci that encompassed a

1 TADA gene divided into three groups: 1) the overlapping TADA gene matched the consensus
2 driver gene, e.g., *SHANK3* for Phelan-McDermid syndrome (22q13.3 deletion) or *NSD1* for
3 Sotos syndrome (5q35.2 deletion) (59, 60); 2) a TADA gene emerged that did not match the
4 previously predicted driver gene(s) within the region, such as *HDLBP* at 2q37.3 (Fig. 3F),
5 where *HDAC4* has been hypothesized as a driver gene (61, 62); and 3) no previous gene had
6 been established within the GD locus, such as *BCL11A* at 2p15-p16.1. One GD locus, 11q13.2-
7 q13.4, had two genes with independent ASD associations in this study (*SHANK2* and *KMT5B*,
8 Fig. 3G), highlighting that many GDs are the consequence of risk conferred by multiple genes
9 within the CNV segment, including many genes likely exerting small effects that our current
10 sample sizes are not sufficiently powered to detect (10).

11


12 **Relationship of ASD genes with GWAS signal**

13 Common variation plays an important role in ASD risk (4), as expected given the high
14 heritability (3). While the specific common variants influencing risk remain largely unknown,
15 recent genome-wide association studies (GWAS) have revealed a handful of associated loci (63).
16 What has become apparent from other GWAS studies, especially those relating GWAS findings
17 to the genes they might influence, is that risk variants commonly influence expression of nearby
18 genes (64). Thus, we asked if there was evidence that common genetic variation within or near
19 the 99 identified genes (within 10 Kb) influences ASD risk or other traits related to ASD risk.
20 Note that among the first five genome-wide significant ASD hits from the current largest GWAS
21 (63), *KMT2E* is a “double hit” – clearly implicated by the GWAS and also in the list of 99 FDR
22 ≤ 0.1 genes described here.

23

1 To explore this question more thoroughly, we ran a gene set enrichment analysis of our 99
2 TADA genes against GWAS summary statistics using MAGMA (65) to integrate the signal for
3 those statistics over each gene using brain-expressed protein-coding genes as our background.
4 We used results from six GWAS datasets: ASD, schizophrenia (SCZ), major depressive disorder
5 (MDD), and attention deficit hyperactive disorder (ADHD), which are all positively genetically
6 correlated with ASD and with each other; educational attainment (EA), which is positively
7 correlated with ASD and negatively correlated with schizophrenia and ADHD; and, as a negative
8 control, human height (Table S7) (63, 66-77). Correcting for six analyses, we observed
9 significant enrichment emerging from the SCZ and EA GWAS results only (Fig. 3H). Curiously,
10 the ASD and ADHD GWAS signals were not enriched in the 99 ASD genes. Although in some
11 ways these results are counterintuitive, one obvious confounder is power (Fig. 3I). Effective
12 cohort sizes for the SCZ, EA, and height GWAS dwarf that for ASD, and the quality of GWAS
13 signal strongly increases with sample size. Thus, for results from well-powered GWAS, it is
14 reassuring that there is no signal for height, yet clearly detectable signal for two traits genetically
15 correlated to ASD: SCZ and EA.

16



1
2 **Figure 4. Phenotypic and functional categories of ASD-associated genes.** **A**, The frequency of
3 disruptive de novo variants (e.g. PTVs or missense variants with MPC ≥ 1) in ascertained ASD
4 and ascertained NDD cases (Table S4) is shown for the 99 ASD-associated genes (selected genes
5 labeled). Fifty genes with a higher frequency in ASD are designated ASD-predominant (ASD_P),
6 while the 46 genes more frequently mutated in NDD are designated as ASD_{NDD}. Three genes
7 with similar frequency in the two disorders are unassigned (BCL11A, DNMT3A, and KCNMA1).
8 Three genes marked with a star (UBR1, MAP1A, and NUP155) are included in the ASD_P
9 category on the basis of case-control data (Table S4), which are not shown in this plot. **B**, ASD
10 cases with disruptive de novo variants in ASD genes show delayed walking compared to ASD
11 cases without such de novo variants, and the effect is greater for those with disruptive de novo
12 variants in ASD_{NDD} genes. **C**, Similarly, cases with disruptive de novo variants in ASD_{NDD} genes
13 and, to a lesser extent, ASD_P genes have a lower full-scale IQ than other ASD cases. **D**, Despite
14 the association between de novo variants in ASD genes and cognitive impairment shown in 'C',
15 an excess of disruptive de novo variants is observed in cases without intellectual disability (FSIQ
16 ≥ 70) or with an IQ above the cohort median (FSIQ ≥ 82). **E**, Along with the phenotypic division
17 (A), genes can also be classified functionally into four groups (gene expression regulation

1 (*GER*), neuronal communication (*NC*), cytoskeleton, and other) based on gene ontology and
2 research literature. The 99 ASD risk genes are shown in a mosaic plot divided by gene function
3 and, from 'A', the ASD vs. NDD variant frequency, with the area of each box proportional to the
4 number of genes. Statistical tests: B, C, t-test; D, chi-square with 1 degree of freedom.
5 Abbreviations: PTV: protein-truncating variant; pLI: probability loss-of-function intolerant;
6 MPC: missense badness, PolyPhen-2, and constraint; FSIQ: full-scale IQ.

7 8 **Relationship between ASD and other neurodevelopmental disorder genes**

9 Sibling studies yield high heritability estimates in ASD (3), suggesting a high contribution from
10 inherited genetic risk factors, but comparable estimates of heritability in severe NDD, often
11 including intellectual disability, are low (78). Consistent with a genomic architecture
12 characterized by few inherited risk factors, exome studies identify an even higher frequency of
13 gene-disrupting *de novo* variants in severe NDD than in ASD (23, 26). As with ASD, these *de*
14 *novo* variants converge on a small number of genes, enabling numerous NDD-associated genes
15 to be identified (22-26). Because at least 30% of ASD subjects have comorbid intellectual
16 disability and/or other NDD, it is unsurprising that many genes confer risk to both disorders, as
17 documented previously (79) and in this dataset (Fig. 4A). Distinguishing genes that, when
18 disrupted, lead to ASD more frequently than NDD might shed new light on how atypical
19 neurodevelopment maps onto the relative deficits in social dysfunction and the repetitive and
20 restrictive behaviors in ASD.

21
22 To partition the 99 ASD genes in this manner, we compiled data from 5,264 trios ascertained for
23 severe NDD (Table S8). Considering disruptive *de novo* variants – which we define here as *de*
24 *novo* PTVs or missense variants with MPC ≥ 1 – we compared the relative frequency, *R*, of *de*
25 *novo* variants in ASD- or NDD-ascertained trios. Genes with $R > 1.25$ were classified as ASD-
26 predominant (ASD_P, 47 genes), while those with $R < 0.8$ were classified as ASD with NDD
27 (ASD_{NDD}, 46 genes). An additional three genes were assigned to the ASD_P group on the basis of
28 case-control data, while three were unassigned (Fig. 4A). For this partition, we then evaluated

1 transmission of rare PTVs (relative frequency < 0.001) from parents to their affected offspring:
2 for ASD_P genes, 51 such PTVs were transmitted and 23 were not (transmission disequilibrium
3 test, p=0.001), whereas, for ASD_{NDD} genes, 16 were transmitted and 13 were not (p=0.25). Note
4 that the frequency of PTVs in parents is also markedly greater in ASD_P genes (1.48 per gene)
5 than in ASD_{NDD} genes (0.80 per gene) and these frequencies are significantly different (p=0.005,
6 binomial test), while the frequency of *de novo* PTVs in probands is not markedly different (92 in
7 ASD_P genes, 114 in ASD_{NDD} genes, p=0.14, binomial test with probability of success = 0.498
8 [PTV in ASD_P gene]). Thus, the count of PTVs in ASD_P genes in parents and their segregation to
9 ASD offspring strongly supports this classification, whereas the count of *de novo* PTVs shows
10 only a trend for higher frequencies in ASD_{NDD} genes.

11
12 Consistent with this partition, ASD subjects who carry disruptive *de novo* variants in ASD_{NDD}
13 genes walk 2.4 ± 1.2 months later (Fig. 4B; $p=1.6 \times 10^{-4}$, t-test, df=238) and have an IQ 11.9 ± 6.1
14 points lower (Fig. 4C; $p=1.7 \times 10^{-4}$, t-test, df=265), on average, than ASD subjects who carry
15 disruptive *de novo* variants in ASD_P genes (Table S9). Both sets of subjects differ significantly
16 from the rest of the ASD cohort with respect to IQ and age of walking (Fig. 4B, 4C; Table S9).
17 While the data support some overall distinction between the genes identified in ASD and NDD
18 *en masse*, we cannot definitively identify which specific genes are distinct at present.

19

20 **Burden of mutations in ASD as a function of IQ**

21 Within the set of 6,430 family-based ASD cases, 3,010 had a detected *de novo* variant and either
22 a recorded full-scale IQ or a clinical assessment of ID. We partitioned these subjects into those
23 with $IQ \geq 70$ (69.4%) versus those with $IQ < 70$ (30.6%), then characterized the burden of *de*
24 *nov*o variants within these groups. ASD subjects in the lower IQ group carry a greater burden of


1 *de novo* variants, relative to both expectation and the high IQ group, in the two top tiers of PTVs
2 and the top tier of missense variants (Fig. 4D). Excess burden, however, is not concentrated
3 solely in the low IQ group, but also observed in the two top PTV tiers for the high IQ group (Fig.
4 4D). Similar patterns were observed if we repeat the analysis partitioning the sample at $IQ < 82$
5 (46.3%) versus $IQ \geq 82$ (53.7%), which was the mean IQ after removing affected subjects who
6 carry disruptive variants in the 99 ASD genes (Fig. 4C). Finally, considering the 99 ASD-
7 associated genes only, there are significant contributions to the association signal from the high
8 IQ group, as documented by model-driven simulations accounting for selection bias due to an
9 FDR threshold (Supplementary Methods). Thus, the signal for association, mediated by
10 mutation, is not solely limited to the low IQ subjects, supporting the idea that *de novo* variants do
11 not solely impair cognition (80).

12

13 **Functional dissection of ASD genes**

14 Given the substantial increase in ASD gene discovery compared to our previous analyses, we
15 leveraged the ASD-associated gene list to provide high-level functional insight into ASD
16 neurobiology. Past analyses have identified two major functional groups of ASD-associated
17 genes: those involved in gene expression regulation (GER), including chromatin regulators and
18 transcription factors, and those involved in neuronal communication (NC), including synaptic
19 function (5, 10). A simple gene ontology analysis with the new list of 99 ASD genes replicates
20 this finding, identifying 16 genes in category GO:0006357 “regulation of transcription from
21 RNA polymerase II promoter” (5.7-fold enrichment, $FDR=6.2 \times 10^{-6}$) and 9 genes in category
22 GO:0007268: “synaptic transmission” (5.0-fold enrichment, $FDR=3.8 \times 10^{-3}$). To assign genes to
23 the GER and NC categories for further analyses, we used a combination of gene ontology and
24 primary literature research as described in the Supplementary Methods (Table S10 and Fig. 4E).

1 Considering the 20 genes not assigned to the GER and NC categories, we see the emergence of a
2 new functional group of nine “cytoskeleton genes”, based on annotation with the gene ontology
3 term GO:0007010 “cytoskeleton organization” or related child terms. The remaining 11 genes
4 are described as “Other” (Table S10 and Fig. 4E), many of which have roles in signaling
5 cascades and/or ubiquitination.
6



1
 2 **Figure 5. Analysis of 99 ASD-associated genes in the context of gene expression data.**
 3 **A**, GTEx bulk RNA-seq data from 53 tissues was processed to identify genes enriched in specific
 4 tissues. Gene set enrichment was performed for the 99 ASD genes and four subsets (ASD_p,
 5 ASD_{NDD}, GER, NC) for each tissue. Five representative tissues are shown here, including cortex,
 6 which showed the greatest degree of enrichment (OR=3.7; $p=3.0 \times 10^{-6}$). **B**, BrainSpan (81) bulk
 7 RNA-seq data across 10 developmental stages was used to plot the normalized expression of the
 8 98 brain-expressed ASD genes across development, split by the four subsets. **C**, A t-statistic was
 9 calculated comparing prenatal to postnatal expression in the BrainSpan data. The t-statistic
 10 distribution of the 99 ASD-associated genes shows a prenatal bias ($p=3 \times 10^{-5}$), which is

1 especially pronounced for GER genes ($p=2\times 10^{-9}$), while NC genes are postnatally biased
2 ($p=0.06$). **D**, The cumulative number of ASD-associated genes expressed in RNA-seq data for
3 4,261 cells collected from human forebrain across prenatal development (82). **E**, t-SNE analysis
4 identifies 19 clusters with unambiguous cell type in this single-cell expression data. **F**, The
5 enrichment of the 99 ASD-associated genes within cells of each type is represented by color. The
6 most consistent enrichment is observed in maturing and mature excitatory (bottom center) and
7 inhibitory (top right) neurons. **G**, The developmental relationships of the 19 clusters is indicated
8 by black arrows, with the inhibitory lineage shown on the left (cyan), excitatory lineage in the
9 middle (magenta), and non-neuronal cell types on the right (grey). The proportion of the 99
10 ASD-associated genes observed in at least 25% of cells within the cluster is shown by the pie
11 chart, while the log-transformed p-value of gene set enrichment is shown by the size of the red
12 circle. **H**, The relationship between the number of cells in the cluster (x-axis) and the p-value for
13 ASD gene enrichment (y-axis) is shown for the 19 cell type clusters. Linear regression indicates
14 that clusters with few expressed genes (e.g. C23 newborn inhibitory neurons) have higher p-
15 values than clusters with many genes (e.g. C25 radial glia). **I**, The relationship between the 19
16 cell type clusters using hierarchical clustering based on the 10% of genes with the greatest
17 variability among cell types. Statistical tests: A, t-test; C, Wilcoxon test; E, F, Fisher Exact Test;
18 H, I, Fisher Exact Test. Abbreviations: GTEx: Genotype-Tissue Expression; CP: choroid plexus;
19 OPC: oligodendrocyte progenitor cells; MGE: medial ganglionic eminence; CGE: Caudal
20 ganglionic eminence; IPC: intermediate progenitor cell; t-SNE: t-distributed stochastic neighbor
21 embedding.

22 23 **ASD genes are expressed early in brain development**

24 The 99 ASD-associated genes can thus be subdivided by functional role (55 GER genes and 24
25 NC genes) and phenotypic impact (50 ASD_P genes, 46 ASD_{NDD} genes) to give five gene sets
26 (including the set of all 99). Gene expression data provide the opportunity to evaluate where and
27 when these genes are expressed and can be used as a proxy for where and when neurobiological
28 alterations ensue in ASD. We first evaluated enrichment for these five gene sets in the 53 tissues
29 with bulk RNA-seq data in the Genotype-Tissue Expression (GTEx) resource. To focus on the
30 genes that provide the most insight into tissue type, we selected genes that were expressed in a
31 tissue at a significantly higher level than the remaining 52 tissues, specifically log fold-change >
32 0.5 and FDR<0.05 (t-test, R package limma). Subsequently, we assessed over-representation of
33 each ASD gene set within 53 sets of genes expressed in each tissue relative to a background of
34 all tissue-specific genes in GTEx. At a threshold of $p \leq 9 \times 10^{-4}$, reflecting 53 tissues, enrichment
35 was observed in 11 of the 13 samples of brain tissue, with the strongest enrichment in cortex

1 ($n=30$ genes; $p=3\times 10^{-6}$; OR=3.7; Fig. 5A) and cerebellar hemisphere ($n=41$ genes; $p=3\times 10^{-6}$;
2 OR=2.9; Fig. 5A). Of the four gene subsets, NC genes were the most highly enriched in cortex
3 (FDR= 2×10^{-10} ; OR=22.1; Fig. 5A), while GER genes were the least enriched (FDR=0.63;
4 OR=1.7; Fig. 5A).

5
6 We next leveraged the BrainSpan human neocortex bulk RNA-seq data (83) to assess enrichment
7 of ASD genes across development (Fig. 5B, 5C). Of the 17,484 autosomal protein-coding genes
8 assessed for ASD-association, 13,735 genes (78.5%) were expressed in the neocortex (RPKM \geq
9 0.5 in 80% of samples of at least one neocortical region and developmental period). Of the 99
10 ASD-associated genes, only the cerebellar transcription factor *PAX5* (81) was not expressed in
11 the cortex (78 expected; $p=1\times 10^{-9}$, binomial test). Compared to other genes expressed in the
12 cortex, the remaining 98 ASD genes are expressed at higher levels during prenatal development,
13 but at lower levels during postnatal development (Fig. 5B). To quantify this pattern, we
14 developed a *t*-statistic that assesses the relative prenatal vs. postnatal expression of each of the
15 13,735 protein-coding genes. Using this metric, the 98 cortex-expressed ASD-associated genes
16 showed enrichment in the prenatal cortex ($p=3\times 10^{-5}$, Wilcoxon test; Fig. 5C). The ASD_P and
17 ASD_{NDD} gene sets showed similar patterns (Fig. 5B), though the prenatal bias *t*-statistic was
18 slightly more pronounced for the ASD_{NDD} group ($p=0.0008$; Fig. 5C). In contrast, the functional
19 subdivisions reveal distinct patterns, with the GER genes reaching their highest levels during
20 early to late fetal development (Fig. 5B) with a marked prenatal bias ($p=2\times 10^{-9}$; Fig. 5C), while
21 NC genes are highest between late mid-fetal development and infancy (Fig. 5B) and show a
22 trend towards postnatal bias ($p=0.06$; Fig. 5C). Thus, supporting their role in ASD risk and in
23 keeping with prior analyses (19, 84-86), the ASD genes show higher expression in human
24 neocortex and are expressed early in brain development. The differing expression patterns of

1 GER and NC genes may reflect two distinct periods of ASD susceptibility during development
2 or a single susceptibility period when both functional gene sets are highly expressed in mid- to
3 late fetal development.

4

5 **ASD genes are enriched in maturing and mature inhibitory and excitatory neurons**

6 Prior analyses have implicated excitatory glutamatergic neurons in the cortex and medium spiny
7 neurons in the striatum in ASD (19, 84-86) using a variety of systems analytical approaches,
8 including gene co-expression. Here, we exploit the 99 ASD-associated genes to perform a more
9 direct assessment, leveraging existing single-cell RNA-seq data from 4,261 cells collected from
10 the prenatal human cortex (82), ranging from 6 to 37 post-conception weeks (pcw) with an
11 average of 16.3 pcw (Table S11).


12

13 Following the logic that only genes that were expressed could mediate ASD risk when disrupted,
14 we divided the 4,261 cells into 17 bins by developmental stage and assessed the cumulative
15 distribution of expressed genes by developmental endpoint (Fig. 5D). For each endpoint, a gene
16 was defined as expressed if at least one transcript mapped to this gene in 25% or more of cells
17 for at least one pcw stage. By definition, more genes were expressed as fetal development
18 progressed, with 4,481 genes expressed by 13 pcw and 7,171 genes expressed by 37 pcw. While
19 the majority of ASD-associated genes were expressed at the earliest developmental stages (e.g.
20 66 of 99 at 13 pcw), the most dramatic increase in the number of genes expressed occurred
21 during midfetal development (68 by 19 pcw, rising to 79 by 23 pcw), consistent with the
22 BrainSpan bulk-tissue data (Fig. 5B, 5C). More liberal thresholds for gene expression resulted in
23 higher numbers of ASD-associated genes expressed (Fig. 5D), but the patterns of expression
24 were similar across definitions and when considering gene function or cell type (Fig. S4).

1
2 To investigate the cell types implicated in ASD, we considered 25 cell type clusters identified by
3 t-distributed stochastic neighbor embedding (t-SNE) analysis, of which 19 clusters, containing
4 3,839 cells, were unambiguously associated with a cell type (82) (Fig. 5E, Table S11) and were
5 used for enrichment analysis. Within each cell type cluster, a gene was considered expressed if at
6 least one of its transcripts was detected in 25% or more cells; 7,867 protein coding genes met this
7 criterion in at least one cluster. From cells of each type, by contrasting one cell type to the others,
8 we observed enrichment for the 99 ASD-associated genes in maturing and mature neurons of the
9 excitatory and inhibitory lineages (Fig. 5F, 5G) but not in non-neuronal cells. Early excitatory
10 neurons (C3) expressed the most ASD genes ($\cap=71$ genes, $p < 1 \times 10^{-10}$), while choroid plexus
11 (C20) expressed the fewest ASD genes ($\cap=38$ genes, $p=0.006$); 13 genes were not expressed in
12 any cluster (Fig. 5G). Within the major neuronal lineages, early excitatory neurons (C3) and
13 striatal interneurons (C1) showed the greatest degree of gene set enrichment ($\cap=71$ and $\cap=50$
14 genes, $p < 1 \times 10^{-10}$; Fig. 5F, 5G; Table S11). Overall, maturing and mature neurons in the
15 excitatory and inhibitory lineages showed a similar degree of enrichment, while those in the
16 excitatory lineage expressed the most ASD genes; this difference is due to the larger numbers of
17 genes expressed in excitatory lineage cells (Fig. 5H). The only non-neuronal cell type with
18 significant enrichment for ASD genes was oligodendrocyte progenitor cells (OPCs) and
19 astrocytes (C4; $\cap=60$ genes, $p=1 \times 10^{-5}$). To assess the validity of the t-SNE clusters, we selected
20 10% of the expressed genes showing the greatest variability among the cell types and performed
21 hierarchical clustering (Fig. 5I). This recaptured the division of these clusters by lineage
22 (excitatory vs. inhibitory) and by development stage (radial glia and progenitors vs. neurons).
23

1 Thus, based on the intersection of the ASD-associated genes and three gene expression datasets,
2 we show that all 99 ASD-associated genes are brain expressed; the bulk of these genes show
3 high expression during fetal development, especially during mid-to-late fetal periods; and the
4 vast majority of these genes are expressed in both excitatory and inhibitory neuronal lineages.
5 Enrichment of ASD-associated genes strongly implicates both excitatory and inhibitory neurons
6 in ASD during their maturation in mid-to-late fetal development.

7



1

2 **Figure 6. Functional relationships of ASD risk genes.** A, ASD association data from TADA
 3 (Table S4) is integrated with co-expression data from the midfetal human brain to implicate
 4 additional genes in ASD. The top 100 genes that share edges are shown ($FDR \leq 0.025$). B,
 5 ASD-associated genes form a single protein-protein interaction network with more edges than
 6 expected by chance ($p=0.02$). C, Experimental data, obtained using ChIP and CLIP methods
 7 across multiple species and a wide range of neuronal and non-neuronal tissues types, identified
 8 the regulatory targets of 26 GER genes (top circle). These data were used to assess whether
 9 three functionally-defined groups of ASD-associated genes were enriched for regulatory targets,

1 *represented as arrows, weighted by the total number of regulatory targets for the GER gene. The*
2 *expected number of targets in each functional group was estimated by permutation, controlling*
3 *for brain expression, de novo PTV mutation rate, and pLI. Statistical tests: A, DAWN; B,*
4 *Permutation; C, Permutation. Abbreviations: DAWN: Discovering Association With Networks.*
5

6 **Functional relationships among ASD genes and prediction of novel risk genes**

7 The ASD-associated genes show convergent functional roles (Fig. 4E) and expression patterns in
8 the human cortex (Fig. 5B). It is therefore reasonable to hypothesize that genes co-expressed
9 with these ASD genes might have convergent or auxiliary function and thus contribute to risk.
10 The Discovering Association With Networks (DAWN) approach integrates ASD association
11 with gene co-expression data to identify clusters of genes with highly correlated co-expression,
12 some of which also show strong association signal from TADA (87). Our previous DAWN
13 analysis identified 160 putative ASD risk genes, 146 of which were not highlighted by the ASD
14 association data alone (5). Of these 146, 11 are in our list of 99 ASD-associated genes, reflecting
15 highly significant enrichment ($p=7.9 \times 10^{-10}$, FET). Here, we leveraged the DAWN model using
16 our new TADA results (Table S12) and BrainSpan gene co-expression data from the midfetal
17 human cortex, as implicated in our analyses (Fig. 5B, 5E), to look for additional genes plausibly
18 implicated in risk. DAWN yields 100 genes ($FDR \leq 0.025$), including 40 that are captured in the
19 99 TADA ASD genes and 60 that are not (Fig. 6A). Of these 60 genes, three are associated with
20 NDD (23) and another 15 have been associated with rare genetic disorders (88, 89); of note, six
21 of these have autosomal recessive inheritance (Table S12). If these 60 novel genes impact ASD
22 risk, we would predict the set would be highly enriched in the excitatory and inhibitory cell types
23 (Fig. 5E-5H). This expectation is supported with 38 out of 60 genes being expressed in
24 excitatory cell types ($p < 1.6 \times 10^{-4}$, FET), 25 of which are also expressed in inhibitory cell types
25 ($p < 7.9 \times 10^{-4}$, FET). Furthermore, many of these 60 genes play a role in GER or NC (Fig. 6A).

26

1 We also sought to interpret gene co-expression and enrichment across a broader range of early
2 developmental samples using a common analytical tool, Weighted Gene Coexpression Network
3 Analysis (WGCNA). With WGCNA, we analyzed spatiotemporal co-expression from 177 high-
4 quality BrainSpan samples aged 8 pcw to 1 year, yielding 27 early developmental co-expression
5 modules (Fig. S5, Table S13). If a module captures ASD-related biology, then we would expect
6 to see ASD genes mapping therein. We identified significant over-representation in two modules
7 after correction for multiple testing (Fig. S5, Table S13): M4 contained a significant over-
8 representation of the NC gene set ($p=0.002$, FET, $OR=13.7$, $\cap=5$ genes); and M25 contained a
9 significant over-representation across all 99 ASD genes ($p=3 \times 10^{-11}$, FET, $OR=12.1$, $\cap=17$
10 genes), driven by the GER gene set ($p=9 \times 10^{-16}$, $OR=26.2$, $\cap=17$ genes). With regard to single-
11 cell gene expression, genes in NC-specific M4 showed greatest enrichment in maturing and
12 mature neurons, both excitatory and inhibitory ($p < 0.001$ for each of 6 neuronal cell types, FET),
13 whereas genes in M25 showed enrichment across all 19 cell types ($p < 0.001$ for all cell types,
14 FET).

15
16 GER and NC gene sets play a prominent role in risk for ASD despite their disparate functions,
17 patterns of expression (Fig. 5B), and early developmental co-expression (Fig. 6A and Table
18 S12); however, the manner in which these two gene sets converge on the ASD phenotype
19 remains unclear. We considered whether these genes might have additional, previously
20 unrecognized interactions at the protein-level, for example, an extranuclear role for GER genes.
21 Protein-protein interaction (PPI) analysis (Fig. 6B, Table S14) identified a significant excess of
22 interactions between all ASD genes ($\cap=82$ genes, $p=0.02$), GER genes ($\cap=49$ genes, $p=0.006$),
23 and NC genes ($\cap=12$ genes, $p=0.03$), but not between GER and NC genes ($\cap=2$ genes, $p=1.00$).
24 We therefore evaluated whether the GER genes regulate the NC genes. To perform this analysis,

1 we collated experimentally derived ChIP- and CLIP-seq data identified by searching ChEA,
2 ENCODE, and PubMed (Table S15). We identified at least one dataset of regulatory targets for
3 26 of the 55 GER genes across multiple tissue types (neural tissue in 31% ($n=8$) of genes) and
4 three species (human tissue in 54% ($n=14$) of genes, with mouse/rat accounting for the
5 remainder). Across the 26 genes, 14,925 protein-coding genes were targeted. The regulatory
6 targets of the 26 GER genes were enriched for the same 26 GER genes (1.2-fold over
7 expectation; $p=0.02$) and the other 29 GER genes (1.3-fold over expectation; $p<0.001$), but not
8 NC genes or genes with other functions (Fig. 6C).

9
10 These results raise the possibility that the GER genes do not regulate the NC genes directly, but
11 rather potentially converge with NC genes in downstream processes in maturing neurons.
12 However, these findings must be interpreted with some degree of caution, due to the non-human
13 and non-neural tissues and heterogeneous methodologies. A similar caveat holds for the PPI
14 analysis (Fig. 6b); studies of protein interaction from brain tissue are limited. Therefore, to
15 address these caveats and to provide additional human brain-specific support for this hypothesis,
16 we examined whether GER and NC gene sets relate to well-curated binding sites for *CHD8*, a
17 GER hub gene (Fig. 6C), using human brain-specific ChIP sequencing data from two
18 independent studies. Strong and consistent enrichment for *CHD8* binding sites (Fig. S6) were
19 observed amongst GER genes for *CHD8* sites derived from the human mid-fetal brain at 16-19
20 pcw ($p=0.001$) as well as *CHD8* sites derived from human neural progenitor cells ($p=0.001$),
21 however we did not observe significant enrichment for NC genes ($p=0.10$, $p=0.25$, respectively).

22

23 Discussion

24

1 We explore rare *de novo* and inherited coding variation from 35,584 individuals, including
2 11,986 ASD cases – the largest number of cases analyzed to date – and implicate 99 genes in risk
3 for ASD at $FDR \leq 0.1$ (Fig. 2). The evidence for several of the 99 genes is driven by missense
4 variants, including confirmed gain-of-function mutations in the potassium channel *KCNQ3* and
5 patterns that may similarly reflect gain-of-function or altered function in *DEAF1*, *SCN1A*, and
6 *SLC6A1* (Fig. 3). Twelve of the 99 ASD-associated genes fall in established genomic disorder
7 (GD) loci, a greater number than expected by chance, despite these two data sources being
8 independent. Similarly, we observe substantial overlap with common variants associated with
9 schizophrenia and educational attainment (Fig. 3). Collectively, many of the genes implicated
10 herein provide important new insights into the functional pathways, tissues, cell types, and
11 developmental timing involved in ASD risk, as well as specificity for ASD versus broader NDD
12 phenotypes.

13
14 By comparing mutation frequencies in ASD cases in our study to other studies in which subjects
15 were ascertained for severe neurodevelopmental delay (NDD), we partitioned the 99 ASD-
16 associated genes into two groups: those that occur at a higher frequency in our ASD subjects, 50
17 ASD_P genes, and those that occur at a higher frequency in NDD subjects, 46 ASD_{NDD} genes (Fig.
18 4A). Two additional lines of evidence support the partition: first, cognitive impairment and
19 motor delay are more frequently observed in our subjects (all ascertained for ASD) with
20 mutations in ASD_{NDD} than in ASD_P genes, in keeping with the wider neurodevelopmental impact
21 of the ASD_{NDD} genes (Fig. 4B, 4C); second, while *de novo* PTVs were observed at a similar
22 frequency in ASD_P and ASD_{NDD} genes in ASD subjects, their parents more frequently carried
23 PTVs in ASD_P genes than in ASD_{NDD} genes, and they transmitted them to their offspring far
24 more often. Together, these observations indicate that ASD-associated genes are distributed

1 across a spectrum of phenotypes and selective pressure. At one extreme, gene haploinsufficiency
2 leads to global developmental delay, with impaired cognitive, social, and gross motor skills
3 leading to extreme negative selection (e.g. *ANKRD11* or *ARID1B*). At the other extreme, gene
4 haploinsufficiency leads to ASD, but there is a more modest involvement of other developmental
5 phenotypes and selective pressure (e.g. *GIGYF1* or *ANK2*). This distinction has important
6 ramifications for clinicians, geneticists, and neuroscientists, since it suggests that clearly
7 delineating the impact of these genes across neurodevelopmental dimensions may offer a route to
8 deconvolve the social dysfunction and repetitive behaviors that define ASD from more general
9 neurodevelopmental impairment.

10
11 Observing the convergence of both GER and NC genes in maturing and mature neurons (Fig. S4)
12 raises the question of how they interact. This interaction does not appear to be at the level of
13 direct protein contact (Fig. 6B), despite both gene sets being represented in the PPI dataset. The
14 bias of GER genes towards earlier expression than NC (Fig. 5c), alongside their functional role,
15 raises the hypothesis that the GER genes act through regulation of downstream NC genes.
16 Testing the regulatory targets of 26 GER genes speaks against this simple relationship, since we
17 observed enrichment for the regulation of other GER genes, but not of NC genes. While the
18 heterogeneous data sources and tissue types limit this analysis, if GER genes mediate risk by
19 regulating NC genes, we would expect a clear and strong enrichment signal, which we do not
20 see. Focusing on *CHD8*, a GER gene strongly associated with ASD (Fig. 2) for which regulatory
21 targets have been defined in neuronal tissues including human fetal cortex (90, 91), we show that
22 enrichment of ASD-associated genes in these targets is exclusive to GER genes (Fig. S6).
23 Experimental validation of this surprising result in neural, ideally human, tissues is critical.

24

1 Analyses of the 99 ASD-associated genes in the context of single-cell gene expression data from
2 the developing human cortex (82) implicated mid-to-late fetal development and maturing and
3 mature neurons in both excitatory and inhibitory lineages (Fig. 5). Non-neuronal cells did not
4 show substantial enrichment, with the exception of astrocytes and OPCs that expressed 60 ASD
5 genes (2.7-fold enrichment; $p=0.0002$). Of these 60 genes, 58 overlapped with radial glia, which
6 may reflect shared developmental origins rather than an independent enrichment signal. In
7 contrast to post-mortem findings in ASD brains (92, 93), no enrichment was observed in
8 microglia. These findings validate and extend prior network analyses (19, 84-86) by leveraging a
9 substantially larger ASD gene set and gene expression at single-cell resolution in developing
10 human brains.

11
12 Our enrichment tests (Fig. 5F-H) implicitly assume that the functional consequences of
13 haploinsufficiency are greatest at higher levels of expression, as required for 25% of cells to
14 express the gene. Alternatively, if haploinsufficiency leads to functional consequences even at
15 low levels of gene expression, then earlier developmental stages and more cell types are involved
16 in ASD neurobiology. Because many ASD-associated genes show high expression across a
17 variety of developmental stages, all early in neurodevelopment, we predict that damaging
18 mutations to any one of them alters neurodevelopmental trajectory, perhaps uniquely. Moreover,
19 most of these genes could impact the trajectories of both the excitatory and inhibitory lineages,
20 implying they have a remarkable range of impacts on both excitatory and inhibitory
21 development. If true, this has broad implications for the neurobiology of ASD, including the
22 hopelessness of grasping its nature by studying the impact of one gene in one cell type and in one
23 developmental context at a time. Rather, ASD must arise by some commonality amongst diverse
24 neurodevelopmental trajectories. Any such hypothesis needs to explain convergence on ASD

1 phenotype – with its readily recognizable impairments in social communication and restricted or
2 repetitive behaviors or interests – based on our ASD-associated set of genes. Two related and
3 very general hypotheses are compatible, and they involve inappropriate crosstalk between
4 excitatory and inhibitory neurons: an excitatory-inhibitory imbalance (94) and failed homeostatic
5 control over cortical circuits (95).

6

7 **Conclusion**

8

9 Through an international collaborative effort, the willingness of thousands of families to
10 volunteer, and the integration of data from several large-scale genomic collaborations, we have
11 assembled a cohort of 35,584 samples from which we identify 99 ASD-associated genes ($FDR \leq$
12 0.1; Fig. 2), including some acting through gain-of-function missense variants (Fig. 3). We
13 observe phenotypic distinctions, identifying a group of 50 ASD genes (ASD_P , Fig. 4) that are
14 enriched for ASD features, distinct from cognitive or motor impairments, and consequently
15 subject to more modest selective pressures. We also observe functional distinctions, with 55
16 genes regulating the expression of other genes (GER), 24 genes implicated in neuronal
17 communication (NC), and the remainder enriched for genes that play a role in the cytoskeleton.
18 These functional distinctions are mirrored in gene expression, gene co-expression, and protein-
19 protein interaction data (Fig. 5, 6), but not phenotypically (Fig. S7), although both sets of genes
20 are enriched in maturing and mature excitatory and inhibitory neurons in the fetal brain (Fig. S4).
21 While these gene sets converge in cell type and overlap in expression trajectories, based on
22 currently available data, the NC genes do not appear to be enriched as regulatory targets of the
23 GER genes (Fig. 5 and S6). Identifying the nature of this convergence, especially in ASD-

1 enriched genes, is likely to hold the key to understanding the neurobiology that underlies the
2 ASD phenotype.

3

4 **Acknowledgements**

5

6 We thank the families who participated in this research, without whose contributions genetic
7 studies would be impossible. This study was supported by the National Institute of Mental
8 Health (U01s: MH100209 (to B.D.), MH100229 (to M.J.D.), MH100233 (to J.D.B), &
9 MH100239 (to M.W.S.); U01s: MH111658 (to B.D.), MH111660 (to M.J.D.), MH111661 (to
10 J.D.B), & MH111662 (to S.J.S. and M.W.S.); Supplement to U01 MH100233 (MH100233-03S1
11 to J.D.B.); R37 MH057881 (to B.D.); R01 MH109901 (to S.J.S. M.W.S., A.J.W.); R01
12 MH109900 (to K.R.); and, R01 MH110928 (to S.J.S., M.W.S., A.J.W.)), National Human
13 Genome Research Institute (HG008895), Seaver Foundation, Simons Foundation (SF402281 to
14 S.J.S., M.W.S., B.D., K.R.), and Autism Science Foundation (to S.J.S., S.L.B., E.B.R.). M.E.T.
15 is supported by R01 MH115957 and Simons Foundation (SF573206) and R.C. is supported by
16 NHGRI T32 HG002295-14 and NSF GRFP 2017240332. S.D.R. is supported by the Seaver
17 Foundation. The iPSYCH project is funded by the Lundbeck Foundation (grant numbers R102-
18 A9118 and R155-2014-1724) and the universities and university hospitals of Aarhus and
19 Copenhagen. The Danish National Biobank resource at the Statens Serum Institut was supported
20 by the Novo Nordisk Foundation. Sequencing of iPSYCH samples was supported by grants from
21 the Simons Foundation (SFARI 311789 to M.J.D) and the Stanley Foundation. Other support for
22 this study was received from the NIMH (5U01MH094432-02 to M.J.D). Computational
23 resources for handling and statistical analysis of iPSYCH data on the GenomeDK and
24 Computerome HPC facilities were provided by, respectively, Centre for Integrative Sequencing,

1 iSEQ, Aarhus University, Denmark (grant to A.D.B), and iPSYCH. The iPSYCH study was
2 approved by the Regional Scientific Ethics Committee in Denmark and the Danish Data
3 Protection Agency. The Norwegian Mother and Child Cohort Study is supported by the
4 Norwegian Ministry of Health and Care Services and the Ministry of Education and Research,
5 NIH/NINDS (grant no.1 UO1 NS 047537-01 and grant no.2 UO1 NS 047537-06A1). We are
6 grateful to all the participating families in Norway who take part in this ongoing cohort study and
7 the Autism Birth Cohort Study. This work was also supported by the Research Council Norway
8 grant number 185476 and Wellcome Trust grant number (098051]). For the collection of the
9 cohort in Turin, the Italian Ministry for Education, University and Research (Ministero
10 dell’Istruzione, dell’Università e della Ricerca - MIUR) funded the Department of Medical
11 Sciences under the program “Dipartimenti di Eccellenza 2018 – 2022” Project
12 code D15D18000410001. We also thank the Associazione “Enrico e Ilaria sono con noi”
13 ONLUS and the Fondazione FORMA. The collection of the cohort in Santiago de Compostela,
14 Spain (Angel Carracedo) was supported by the Fundación María José Jove. The collection of the
15 cohort in Madrid, Spain (Mara Parellada) was funded by Instituto de Salud Carlos III
16 (C.0001481, PI14/02103, PI17/00819) and IiSGM. The collection in Japan (Branko Aleksic) was
17 supported by AMED under grant No. JP18dm0107087 and No. JP18dm0207005. The collection
18 in Hong Kong (Brian H.Y. Chung) was supported by the Society for the Relief of Disabled
19 Children, Hong, Kong. For the collection in Germany (Andreas Chiocchetti and Christine M.
20 Freitag), we thank S. Lindlar, J. Heine, and H. Jelen for technical assistance, and H. Zerlaut and
21 C. Lemler for database management. The collection was supported by Saarland University (T6
22 03 10 00-45 to Christine M Freitag); German Research Association DFG (Po 255/17-4 to Fritz
23 Poustka); EC FP6-LIFESCIHEALTH (512158; AUTISM MOLGEN to Annemarie Poustka, and
24 Fritz Poustka); BMBF ERA-NET NEURON project: EUHFAUTISM (EUHFAUTISM-

1 01EW1105 to Christine M Freitag); Landes-Offensive zur Entwicklung wissenschaftlich-
2 ökonomischer Exzellenz (LOEWE): Neuronal Coordination Research Focus Frankfurt (NeFF, to
3 Christine M Freitag), and EC IMI initiative AIMS-2-TRIALS (777394-2 to Christine M Freitag).
4 During the last 3 years, Christine M Freitag has been consultant to Desitin and Roche, receives
5 royalties for books on ASD, ADHD, and MDD, and has been granted research funding by the
6 European Commission (EC), Deutsche Forschungsgemeinschaft (DFG), and the German
7 Ministry of Science and Education (BMBF). The collection in Utah was supported by R01
8 MH094400 (to Hilary Coon). The collection in Siena (Alessandra Renieri) was supported by
9 the “Cell lines and DNA bank of Rett Syndrome, X-linked mental retardation and other genetic
10 diseases”, member of the Telethon Network of Genetic Biobanks (project no. GTB12001),
11 funded by Telethon Italy, and of the EuroBioBank network. The PAGES collection in Sweden
12 was supported by R01 MH097849 (to J.D.B.), Supplement to R01 MH097849 (MH097849-02S1
13 to J.D.B.), and R01 MH097849 (to J.D.B.). The collection at University of Pittsburgh (Nancy
14 Minshev) was supported by the Trees Charitable Trust. The collection in Brazil (Maria Rita
15 Passos-Bueno) was supported by Fundação de apoio a pesquisa do estado de São Paulo
16 (FAPESP)/CEPID 2013/08028-1, Conselho Nacional do Desenvolvimento Tecnológico
17 (CNPq)466651/2014-7. For the collection in Finland (Kaija Puura), we thank The Academy of
18 Finland (grant 286284 to T.L.); Competitive State Research Financing of the Expert
19 Responsibility area of Tampere University Hospital (to T.L., K.P.); Signe and Ane Gyllenberg
20 Foundation (to T.L.); Tampere University Hospital Supporting Foundation (to T.L.), European
21 Union (The GEBACO Project no. 028696, to K.P. and M.K.), the Medical Research Fund of
22 Tampere University Hospital (to K.P.), The Child Psychiatric Research Foundation (Finland, to
23 M.K.) and The Emil Aaltonen Foundation (to M.K.). For the collection at UCSF (Lauren A.
24 Weiss), we acknowledge funding sources NIH Exploratory/Developmental Research Grant

1 Award (R21) HD065273 (to L.A.W.), Simons Foundation Autism Research Initiative (SFARI)
2 136720 (to L.A.W.) as well as IMHRO and UCSF-Research Evaluation and Allocation
3 Committee (REAC) support (to L.A.W.). The collection at UIC (Edwin H. Cook) was supported
4 by NICHD P50 HD055751 (to E.H.C), and the sequencing was funded through X01 HG007235.
5 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the
6 Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA,
7 NIMH, and NINDS. DDG2P data used for the analyses described in this manuscript were
8 obtained from <http://www.ebi.ac.uk/gene2phenotype/>. The funders played no role in the design
9 of the study, in the collection, analysis, and interpretation of data, or in writing the manuscript.
10 We thank Tom Nowakowski (UCSF) for facilitating access to the single-cell gene expression
11 data.

References

1. *Diagnostic and statistical manual of mental disorders : DSM-5*. (Fifth edition. Arlington, VA : American Psychiatric Publishing, ©2013, 2013).
2. J. Baio *et al.*, Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. *MMWR Surveillance Summaries* **67**, 1 (2018).
3. B. H. K. Yip *et al.*, Heritable variation, with little or no maternal effect, accounts for recurrence risk to autism spectrum disorder in Sweden. *Biological psychiatry* **83**, 589-597 (2018).
4. T. Gaugler *et al.*, Most genetic risk for autism resides with common variation. *Nature genetics* **46**, 881-885 (2014).
5. S. De Rubeis *et al.*, Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* **515**, 209-215 (2014).
6. I. Iossifov *et al.*, The contribution of de novo coding mutations to autism spectrum disorder. *Nature* **515**, 216-221 (2014).
7. I. Iossifov *et al.*, De novo gene disruptions in children on the autistic spectrum. *Neuron* **74**, 285-299 (2012).
8. B. J. O'Roak *et al.*, Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature* **485**, 246-250 (2012).
9. Stephan J. Sanders *et al.*, Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams Syndrome region, are strongly associated with autism. *Neuron* **70**, 863-885 (2011).
10. S. J. Sanders *et al.*, Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. *Neuron* **87**, 1215-1233 (2015).
11. S. J. Sanders *et al.*, De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature* **485**, 237-241 (2012).
12. S. Dong *et al.*, De novo insertions and deletions of predominantly paternal origin are associated with autism spectrum disorder. *Cell Rep* **9**, 16-23 (2014).
13. D. Levy *et al.*, Rare de novo and transmitted copy-number variation in autistic spectrum disorders. *Neuron* **70**, 886-897 (2011).
14. J. Sebat *et al.*, Strong association of de novo copy number mutations with autism. *Science (New York, N.Y.)* **316**, 445-449 (2007).
15. X. He *et al.*, Integrated model of de novo and inherited genetic variants yields greater power to identify risk genes. *PLoS genetics* **9**, e1003671 (2013).
16. K. E. Samocha *et al.*, A framework for the interpretation of de novo mutation in human disease. *Nature genetics* **46**, 944-950 (2014).
17. R. Ben-Shalom *et al.*, Opposing effects on NaV1.2 function underlie differences between SCN2A variants observed in individuals with autism spectrum disorder or infantile seizures. *Biological psychiatry* **82**, 1-9 (2017).
18. R. Bernier *et al.*, Disruptive CHD8 mutations define a subtype of autism early in development. *Cell* **158**, 263-276 (2014).
19. A. J. Willsey *et al.*, Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. *Cell* **155**, 997-1007 (2013).
20. J. D. Buxbaum *et al.*, The autism sequencing consortium: large-scale, high-throughput sequencing in autism spectrum disorders. *Neuron* **76**, 1052-1056 (2012).

21. S. L. Bishop *et al.*, Identification of developmental and behavioral markers associated with genetic abnormalities in autism spectrum disorder. *American Journal of Psychiatry* **174**, appi.aj 2017.2011 (2017).
22. J. de Ligt *et al.*, Diagnostic exome sequencing in persons with severe intellectual disability. *The New England journal of medicine* **367**, 1921-1929 (2012).
23. S. Deciphering Developmental Disorders, Prevalence and architecture of de novo mutations in developmental disorders. *Nature* **542**, 433-438 (2017).
24. C. Gilissen *et al.*, Genome sequencing identifies major causes of severe intellectual disability. *Nature* **511**, 344-347 (2014).
25. A. Rauch *et al.*, Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet (London, England)* **380**, 1674-1682 (2012).
26. S. H. Lelieveld *et al.*, Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nature neuroscience* **19**, 1194-1196 (2016).
27. H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics (Oxford, England)* **25**, 1754-1760 (2009).
28. A. McKenna *et al.*, The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome research* **20**, 1297-1303 (2010).
29. F. K. Satterstrom *et al.*, ASD and ADHD have a similar burden of rare protein-truncating variants. *bioRxiv*, (2018).
30. M. Lek *et al.*, Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285-291 (2016).
31. J. A. Kosmicki *et al.*, Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. *Nature genetics* **49**, 504-510 (2017).
32. K. E. Samocha *et al.*, Regional missense constraint improves variant deleteriousness prediction. *bioRxiv*, (2017).
33. R. A. Power *et al.*, Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or substance abuse vs their unaffected siblings. *JAMA psychiatry* **70**, 22-30 (2013).
34. D. L. Christensen *et al.*, Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. *Morbidity and mortality weekly report. Surveillance summaries* **65**, 1-23 (2016).
35. A. K. Halladay *et al.*, Sex and gender differences in autism spectrum disorder: Summarizing evidence gaps and identifying emerging areas of priority. *Molecular autism* **6**, 36 (2015).
36. D. M. Werling, The role of sex-differential biology in risk for autism spectrum disorder. *Biology of Sex Differences* **7**, 1-18 (2016).
37. R. E. Slager, T. L. Newton, C. N. Vlangos, B. Finucane, S. H. Elsea, Mutations in RAI1 associated with Smith-Magenis syndrome. *Nature genetics* **33**, 466-468 (2003).
38. M. J. Bottomley *et al.*, The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation. *Nature structural biology* **8**, 626-633 (2001).
39. A. T. Vulto-van Silfhout *et al.*, Mutations affecting the SAND domain of DEAF1 cause intellectual disability with severe speech impairment and behavioral problems. *Am J Hum Genet* **94**, 649-661 (2014).

40. L. Chen *et al.*, Functional analysis of novel DEAF1 variants identified through clinical exome sequencing expands DEAF1-associated neurodevelopmental disorder (DAND) phenotype. *Human mutation* **38**, 1774-1785 (2017).
41. H. O. Heyne *et al.*, De novo variants in neurodevelopmental disorders with epilepsy. *Nature genetics* **50**, 1048-1053 (2018).
42. F. Miceli *et al.*, Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **35**, 3782-3793 (2015).
43. S. Maljevic *et al.*, Novel KCNQ3 mutation in a large family with benign familial neonatal epilepsy: A rare cause of neonatal seizures. *Molecular Syndromology* **7**, 189-196 (2016).
44. M. J. Landrum *et al.*, ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic acids research* **42**, D980-D985 (2014).
45. K. M. Johannesen *et al.*, Defining the phenotypic spectrum of SLC6A1 mutations. *Epilepsia* **59**, 389-402 (2018).
46. C. Leroy *et al.*, The 2q37-deletion syndrome: an update of the clinical spectrum including overweight, brachydactyly and behavioural features in 14 new patients. *Eur J Hum Genet* **21**, 602-612 (2013).
47. B. P. Coe *et al.*, Refining analyses of copy number variation identifies specific genes associated with developmental delay. *Nature genetics* **46**, 1063-1071 (2014).
48. G. M. Cooper *et al.*, A copy number variation morbidity map of developmental delay. *Nature genetics* **43**, 838-846 (2011).
49. G. B. Schaefer, N. J. Mendelsohn, Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genetics in medicine : official journal of the American College of Medical Genetics* **15**, 399-407 (2013).
50. P. J. Jensik, J. I. Huggenvik, M. W. Collard, Identification of a nuclear export signal and protein interaction domains in deformed epidermal autoregulatory factor-1 (DEAF-1). *Journal of Biological Chemistry* **279**, 32692-32699 (2004).
51. Y. Chen *et al.*, Modeling Rett syndrome using TALEN-edited MECP2 mutant cynomolgus monkeys. *Cell* **169**, 945-955 (2017).
52. S. J. Sanders *et al.*, Progress in understanding and treating SCN2A-mediated disorders. *Trends in neurosciences* **41**, 442-456 (2018).
53. L. Claes *et al.*, De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. *Am J Hum Genet* **68**, 1327-1332 (2001).
54. B. M. Li *et al.*, Autism in Dravet syndrome: Prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. *Epilepsy and Behavior* **21**, 291-295 (2011).
55. C. Rosander, T. Hallbook, Dravet syndrome in Sweden: a population-based study. *Developmental medicine and child neurology* **57**, 628-633 (2015).
56. F. Ragona *et al.*, Dravet syndrome: Early clinical manifestations and cognitive outcome in 37 Italian patients. *Brain and Development* **32**, 71-77 (2010).
57. J. C. Mulley *et al.*, SCN1A mutations and epilepsy. *Human mutation* **25**, 535-542 (2005).
58. K. A. Mattison *et al.*, SLC6A1 variants identified in epilepsy patients reduce gamma-aminobutyric acid transport. *Epilepsia* **59**, e135-e141 (2018).
59. L. Soorya *et al.*, Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. *Molecular autism* **4**, 18 (2013).

60. S. Turkmen *et al.*, Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes. *Eur J Hum Genet* **11**, 858-865 (2003).
61. P. Villavicencio-Lorini *et al.*, Phenotypic variant of Brachydactyly-mental retardation syndrome in a family with an inherited interstitial 2q37.3 microdeletion including HDAC4. *Eur J Hum Genet* **21**, 743-748 (2013).
62. S. R. Williams *et al.*, Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. *Am J Hum Genet* **87**, 219-228 (2010).
63. J. Grove *et al.*, Common risk variants identified in autism spectrum disorder. *bioRxiv*, (2017).
64. M. E. Hauberg *et al.*, Large-scale identification of common trait and disease variants affecting gene expression. *American journal of human genetics* **100**, 885-894 (2017).
65. C. A. de Leeuw, J. M. Mooij, T. Heskes, D. Posthuma, MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput Biol* **11**, e1004219 (2015).
66. J. Zheng *et al.*, LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics (Oxford, England)* **33**, 272-279 (2017).
67. D. Demontis *et al.*, Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nature genetics*, (2018).
68. S. Ripke *et al.*, Genome-wide association study identifies five new schizophrenia loci. *Nature genetics* **43**, 969--976 (2011).
69. A. Okbay *et al.*, Genome-wide association study identifies 74 loci associated with educational attainment. *Nature* **533**, 539 (2016).
70. C. Schizophrenia Working Group of the Psychiatric Genomics, Biological insights from 108 schizophrenia-associated genetic loci. *Nature* **511**, 421-427 (2014).
71. S. Ripke *et al.*, A mega-analysis of genome-wide association studies for major depressive disorder. *Molecular psychiatry* **18**, 497-511 (2013).
72. N. R. Wray *et al.*, Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nature genetics* **50**, 668-681 (2018).
73. L. Yengo *et al.*, Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Human molecular genetics* **27**, 3641-3649 (2018).
74. B. M. Neale *et al.*, Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* **49**, 884-897 (2010).
75. J. J. Lee *et al.*, Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nature genetics* **50**, 1112-1121 (2018).
76. C. A. Rietveld *et al.*, GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. *Science* **340**, 1467-1471 (2013).
77. S. Ripke *et al.*, Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nature genetics* **45**, 1150-1159 (2013).
78. A. Reichenberg *et al.*, Discontinuity in the genetic and environmental causes of the intellectual disability spectrum. *Proceedings of the National Academy of Sciences* **113**, 1098-1103 (2016).
79. D. Pinto *et al.*, Functional impact of global rare copy number variation in autism spectrum disorders. *Nature* **466**, 368-372 (2010).

80. E. B. Robinson *et al.*, Autism spectrum disorder severity reflects the average contribution of de novo and familial influences. *Proceedings of the National Academy of Sciences of the United States of America* **111**, 15161-15165 (2014).
81. H. J. Kang *et al.*, Spatio-temporal transcriptome of the human brain. *Nature* **478**, 483-489 (2011).
82. T. J. Nowakowski *et al.*, Spatiotemporal gene expression trajectories reveal developmental hierarchies of the human cortex. *Science* **358**, 1318-1323 (2017).
83. M. J. Hawrylycz *et al.*, An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature* **489**, 391-399 (2012).
84. N. N. Parikshak *et al.*, Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. *Cell* **155**, 1008-1021 (2013).
85. X. Xu, A. B. Wells, D. R. O'Brien, A. Nehorai, J. D. Dougherty, Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **34**, 1420-1431 (2014).
86. J. Chang, S. R. Gilman, A. H. Chiang, S. J. Sanders, D. Vitkup, Genotype to phenotype relationships in autism spectrum disorders. *Nature neuroscience* **18**, 191-198 (2014).
87. L. Liu *et al.*, DAWN: a framework to identify autism genes and subnetworks using gene expression and genetics. *Molecular autism* **5**, 1-18 (2014).
88. Online Mendelian Inheritance in Man, OMIM.
89. C. F. Wright *et al.*, Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. *Lancet (London, England)* **385**, 1305-1314 (2015).
90. A. Sugathan *et al.*, CHD8 regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. *Proceedings of the National Academy of Sciences of the United States of America* **111**, E4468-4477 (2014).
91. J. Cotney *et al.*, The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment. *Nat Commun* **6**, 6404 (2015).
92. M. J. Gandal *et al.*, Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. *Science (New York, N.Y.)* **359**, 693-697 (2018).
93. I. Voineagu *et al.*, Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature* **474**, 380-384 (2011).
94. J. L. Rubenstein, M. M. Merzenich, Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes, brain, and behavior* **2**, 255-267 (2003).
95. S. B. Nelson, V. Valakh, Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. *Neuron* **87**, 684-698 (2015).